Abstract
Late complications of allogeneic hematopoietic stem cell transplantation (HSCT) include a risk of secondary malignancies. Optimization for early diagnosis and treatment of oral premalignant or malignant lesions requires an assessment of potential predisposing risk factors. The medical records of patients who developed oral epithelial dysplasia (OED) and oral squamous cell carcinoma (OSCC) following allogeneic-HSCT were reviewed. Data on HSCT course, chronic graft-versus-host disease (cGVHD), and clinical outcome were recorded; landmark survival was calculated. Twenty-six patients with OED (n=8) and OSCC (n=18) were identified with a median follow-up of 26.5 and 21.5 months, respectively. Premalignant and malignant oral lesions were diagnosed at a median time of 2.5 and 8 years after HSCT, respectively. Chronic GVHD was present in 96% of patients and of these, 96% had oral involvement. Multifocal oral cancer was found in 28% of cases, and localized recurrence was observed in 44% of cases. These results suggest that oral cGVHD may be considered a potential risk factor for the development of OSCC following allogeneic-HSCT. The observation that oral cancers were frequently multifocal and recurred locally suggests that these cancers may be more aggressive. Vigilant follow-up and coordination of care are critical.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336: 897–904.
Bhatia S, Louie AD, Bhatia R, O’Donnell MR, Fung H, Kashyap A et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001; 19: 464–471.
Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL . New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003; 21: 1352–1358.
Otsubo H, Yokoe H, Miya T, Atsuta F, Miura N, Tanzawa H et al. Gingival squamous cell carcinoma in a patient with chronic graft-versus-host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 84: 171–174.
Gluckman E, Socie G, Devergie A, Bourdeau-Esperou H, Traineau R, Cosset JM . Bone marrow transplantation in 107 patients with severe aplastic anemia using cyclophosphamide and thoraco-abdominal irradiation for conditioning: long-term follow-up. Blood 1991; 78: 2451–2455.
Sacchi S, Marcheselli L, Bari A, Marcheselli R, Pozzi S, Luminari S et al. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica 2008; 93: 398–404.
Shimada K, Yokozawa T, Atsuta Y, Kohno A, Maruyama F, Yano K et al. Solid tumors after hematopoietic stem cell transplantation in Japan: incidence, risk factors and prognosis. Bone Marrow Transplant 2005; 36: 115–121.
Demarosi F, Lodi G, Carrassi A, Soligo D, Sardella A . Oral malignancies following HSCT: graft versus host disease and other risk factors. Oral Oncol 2005; 41: 865–877.
Witherspoon RP, Deeg HJ, Storb R . Secondary malignancies after marrow transplantation for leukemia or aplastic anemia. Transplant Sci 1994; 4: 33–41.
Socie G, Scieux C, Gluckman E, Soussi T, Clavel C, Saulnier P et al. Squamous cell carcinomas after allogeneic bone marrow transplantation for aplastic anemia: further evidence of a multistep process. Transplantation 1998; 66: 667–670.
Kutler DI, Auerbach AD, Satagopan J, Giampietro PF, Batish SD, Huvos AG et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg 2003; 129: 106–112.
Chen MH, Chang PM, Li WY, Hsiao LT, Hong YC, Liu CY et al. High incidence of oral squamous cell carcinoma independent of HPV infection after allogeneic hematopoietic SCT in Taiwan. Bone Marrow Transplant 2011; 46: 567–572.
Montebugnoli L, Gissi DB, Marchetti C, Foschini MP . Multiple squamous cell carcinomas of the oral cavity in a young patient with graft-versus-host disease following allogenic bone marrow transplantation. Int J Oral Maxillofac Surg (e-pub ahead of print 14 December 2010).
Abdelsayed RA, Sumner T, Allen CM, Treadway A, Ness GM, Penza SL . Oral precancerous and malignant lesions associated with graft-versus-host disease: report of 2 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 93: 75–80.
Curtis RE, Metayer C, Rizzo JD, Socie G, Sobocinski KA, Flowers ME et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 2005; 105: 3802–3811.
Bagan J, Scully C, Jimenez Y, Martorell M . Proliferative verrucous leukoplakia: a concise update. Oral Dis 2010; 16: 328–332.
Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277–300.
Funk GF, Karnell LH, Robinson RA, Zhen WK, Trask DK, Hoffman HT . Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report. Head Neck 2002; 24: 165–180.
Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM, Tsai CC . Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med 1995; 24: 450–453.
Rizzo JD, Curtis RE, Socie G, Sobocinski KA, Gilbert E, Landgren O et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 1175–1183.
Deeg HJ, Sanders J, Martin P, Fefer A, Neiman P, Singer J et al. Secondary malignancies after marrow transplantation. Exp Hematol 1984; 12: 660–666.
Witherspoon RP, Fisher LD, Schoch G, Martin P, Sullivan KM, Sanders J et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 1989; 321: 784–789.
Socie G, Henry-Amar M, Devergie A, Wibault P, Neiger M, Cosset JM et al. Poor clinical outcome of patients developing malignant solid tumors after bone marrow transplantation for severe aplastic anemia. Leuk Lymphoma 1992; 7: 419–423.
Witherspoon RP, Storb R, Pepe M, Longton G, Sullivan KM . Cumulative incidence of secondary solid malignant tumors in aplastic anemia patients given marrow grafts after conditioning with chemotherapy alone. Blood 1992; 79: 289–291.
Deeg HJ, Witherspoon RP . Risk factors for the development of secondary malignancies after marrow transplantation. Hematol Oncol Clin North Am 1993; 7: 417–429.
Socie G, Henry-Amar M, Bacigalupo A, Hows J, Tichelli A, Ljungman P et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med 1993; 329: 1152–1157.
Lowsky R, Lipton J, Fyles G, Minden M, Meharchand J, Tejpar I et al. Secondary malignancies after bone marrow transplantation in adults. J Clin Oncol 1994; 12: 2187–2192.
Bhatia S, Ramsay NK, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633–3639.
Deeg HJ, Socie G, Schoch G, Henry-Amar M, Witherspoon RP, Devergie A et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996; 87: 386–392.
Andre M, Henry-Amar M, Blaise D, Colombat P, Fleury J, Milpied N et al. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 1998; 92: 1933–1940.
Kolb HJ, Socie G, Duell T, Van Lint MT, Tichelli A, Apperley JF et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med 1999; 131: 738–744.
Socie G, Curtis RE, Deeg HJ, Sobocinski KA, Filipovich AH, Travis LB et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 2000; 18: 348–357.
Lishner M, Patterson B, Kandel R, Fyles G, Curtis JE, Meharchand J et al. Cutaneous and mucosal neoplasms in bone marrow transplant recipients. Cancer 1990; 65: 473–476.
Vose JM, Kennedy BC, Bierman PJ, Kessinger A, Armitage JO . Long-term sequelae of autologous bone marrow or peripheral stem cell transplantation for lymphoid malignancies. Cancer 1992; 69: 784–789.
Bradford CR, Hoffman HT, Wolf GT, Carey TE, Baker SR, McClatchey KD . Squamous carcinoma of the head and neck in organ transplant recipients: possible role of oncogenic viruses. Laryngoscope 1990; 100 (2 Part 1): 190–194.
Millen FJ, Rainey MG, Hows JM, Burton PA, Irvine GH, Swirsky D . Oral squamous cell carcinoma after allogeneic bone marrow transplantation for Fanconi anaemia. Br J Haematol 1997; 99: 410–414.
Zhang L, Epstein JB, Poh CF, Berean K, Lam WL, Zhang X et al. Comparison of HPV infection, p53 mutation and allelic losses in post-transplant and non-posttransplant oral squamous cell carcinomas. J Oral Pathol Med 2002; 31: 134–141.
Khan FM, Sy S, Louie P, Ugarte-Torres A, Berka N, Sinclair G et al. Genomic instability after allogeneic hematopoietic cell transplantation is frequent in oral mucosa, particularly in patients with history of chronic graft-vs-host disease, and rare in nasal mucosa. Blood 2010; 116: 1803–1806.
Faber P, Fisch P, Waterhouse M, Schmitt-Graff A, Bertz H, Finke J et al. Frequent genomic alterations in epithelium measured by microsatellite instability following allogeneic hematopoietic cell transplantation in humans. Blood 2006; 107: 3389–3396.
Themeli M, Petrikkos L, Waterhouse M, Bertz H, Lagadinou E, Zoumbos N et al. Alloreactive microenvironment after human hematopoietic cell transplantation induces genomic alterations in epithelium through an ROS-mediated mechanism: in vivo and in vitro study and implications to secondary neoplasia. Leukemia 2010; 24: 536–543.
Imanguli MM, Swaim WD, League SC, Gress RE, Pavletic SZ, Hakim FT . Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. Blood 2009; 113: 3620–3630.
Chi AC . Squamous cell carcinoma. In: Neville BW, Damm DD, Allen CM, Bouquot JE (eds). Oral and Maxillofacial Pathology, 3rd edn Saunders Elsevier: St Louis, Missouri, 2009 pp 409 and 413.
Janin A, Murata H, Leboeuf C, Cayuela JM, Gluckman E, Legres L et al. Donor-derived oral squamous cell carcinoma after allogeneic bone marrow transplantation. Blood 2009; 113: 1834–1840.
Tomihara K, Dehari H, Yamaguchi A, Abe M, Miyazaki A, Nakamori K et al. Squamous cell carcinoma of the buccal mucosa in a young adult with history of allogeneic bone marrow transplantation for childhood acute leukemia. Head Neck 2009; 31: 565–568.
Lerche CM, Philipsen PA, Poulsen T, Wulf HC . Topical tacrolimus in combination with simulated solar radiation does not enhance photocarcinogenesis in hairless mice. Exp Dermatol 2008; 17: 57–62.
Patel TS, Greer SC, Skinner Jr RB . Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians. Am J Clin Dermatol 2007; 8: 189–194.
Ormerod AD . Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol 2005; 153: 701–705.
Murphy D . Briefing Information. Food and Drug Administration, Pediatric Advisory Committee, 2005 (http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2.htm).
Becker JC, Houben R, Vetter CS, Brocker EB . The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report. BMC Cancer 2006; 6: 7.
Mattsson U, Magnusson B, Jontell M . Squamous cell carcinoma in a patient with oral lichen planus treated with topical application of tacrolimus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 110: e19–e25.
Niwa Y, Terashima T, Sumi H . Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol 2003; 149: 960–967.
Yarosh DB, Pena AV, Nay SL, Canning MT, Brown DA . Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 2005; 125: 1020–1025.
Hearn RM, Kerr AC, Rahim KF, Ferguson J, Dawe RS . Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol 2008; 159: 931–935.
Forastiere A, Koch W, Trotti A, Sidransky D . Head and neck cancer. N Engl J Med 2001; 345: 1890–1900.
Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990; 323: 795–801.
Sturgis EM, Miller RH . Second primary malignancies in the head and neck cancer patient. Ann Otol Rhinol Laryngol 1995; 104: 946–954.
Scully C, Bagan J . Oral squamous cell carcinoma overview. Oral Oncol 2009; 45: 301–308.
Treister NS, Cook Jr EF, Antin J, Lee SJ, Soiffer R, Woo SB . Clinical evaluation of oral chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008; 14: 110–115.
Epstein JB, Gorsky M, Cabay RJ, Day T, Gonsalves W . Screening for and diagnosis of oral premalignant lesions and oropharyngeal squamous cell carcinoma: role of primary care physicians. Can Fam Physician 2008; 54: 870–875.
D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944–1956.
Rethman MP, Carpenter W, Cohen EE, Epstein J, Evans CA, Flaitz CM et al. Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. J Am Dent Assoc 2010; 141: 509–520.
Acknowledgements
The oral medicine specialists (HM, SE, MEC, S-BW and NT) thank the Hematopoietic Cell Transplantation and Head and Neck Oncology departments at their respective institutions for their daily collaboration in the management of these patients. We also extend our gratitude to our patients and their families. Supported in part by NIH Grant CA142106.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Mawardi, H., Elad, S., Correa, M. et al. Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes. Bone Marrow Transplant 46, 884–891 (2011). https://doi.org/10.1038/bmt.2011.77
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2011.77
Keywords
This article is cited by
-
Oral chronic GVHD after allogeneic stem cell transplantation without total body irradiation performed at a young age
Supportive Care in Cancer (2022)
-
Secondary oral cancer following hematopoietic cell transplantation
Bone Marrow Transplantation (2021)
-
Oral white lesion in patients post-hematopoietic stem cell transplantation: a case series demonstrating the diagnostic dilemma
Supportive Care in Cancer (2021)
-
Chronic oral graft-versus-host disease: induction and maintenance therapy with photobiomodulation therapy
Supportive Care in Cancer (2021)
-
Regression of oral proliferative leukoplakia following initiation of ibrutinib therapy in two allogeneic hematopoietic stem cell transplant recipients
Bone Marrow Transplantation (2020)